Published in J Infect Dis on September 10, 2004
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
Resistance to echinocandin-class antifungal drugs. Drug Resist Updat (2007) 4.63
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol (2008) 2.95
Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother (2005) 2.54
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother (2005) 2.07
In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother (2010) 1.88
Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J Infect Dis (2008) 1.82
Fungal echinocandin resistance. Fungal Genet Biol (2009) 1.78
Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. Antimicrob Agents Chemother (2007) 1.76
Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother (2005) 1.75
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother (2007) 1.61
Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother (2005) 1.57
A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design. PLoS Comput Biol (2011) 1.52
Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. J Infect Dis (2013) 1.49
Current perspectives on echinocandin class drugs. Future Microbiol (2011) 1.44
Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother (2006) 1.43
Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother (2008) 1.38
Calcineurin target CrzA regulates conidial germination, hyphal growth, and pathogenesis of Aspergillus fumigatus. Eukaryot Cell (2008) 1.37
Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol (2009) 1.36
Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother (2007) 1.31
Current concepts in antifungal pharmacology. Mayo Clin Proc (2011) 1.26
Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Antimicrob Agents Chemother (2011) 1.25
Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin. Antimicrob Agents Chemother (2010) 1.21
Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2006) 1.21
Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob Agents Chemother (2006) 1.16
Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrob Agents Chemother (2011) 1.10
Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother (2005) 1.08
Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. Antimicrob Agents Chemother (2006) 1.07
Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2007) 1.03
Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrob Agents Chemother (2009) 1.01
Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis. Antimicrob Agents Chemother (2005) 1.01
Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob Agents Chemother (2006) 0.99
Comparison of echinocandin antifungals. Ther Clin Risk Manag (2007) 0.99
Ocular penetration of caspofungin in a rabbit uveitis model. Graefes Arch Clin Exp Ophthalmol (2006) 0.98
Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother (2009) 0.94
Transcriptional activation of heat shock protein 90 mediated via a proximal promoter region as trigger of caspofungin resistance in Aspergillus fumigatus. J Infect Dis (2013) 0.91
Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis. Antimicrob Agents Chemother (2012) 0.90
Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model. Antimicrob Agents Chemother (2007) 0.90
Calcineurin as a Multifunctional Regulator: Unraveling Novel Functions in Fungal Stress Responses, Hyphal Growth, Drug Resistance, and Pathogenesis. Fungal Biol Rev (2014) 0.90
Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections. Antimicrob Agents Chemother (2010) 0.88
Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. J Antimicrob Chemother (2008) 0.87
Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients. Antimicrob Agents Chemother (2010) 0.86
Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis. Antimicrob Agents Chemother (2007) 0.86
Antifungal pharmacokinetics and pharmacodynamics. Cold Spring Harb Perspect Med (2014) 0.85
Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease. Antimicrob Agents Chemother (2006) 0.85
Stage-specific innate immune recognition of Aspergillus fumigatus and modulation by echinocandin drugs. Med Mycol (2008) 0.85
Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2008) 0.85
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis. Antimicrob Agents Chemother (2014) 0.84
Bronchopulmonary disposition of micafungin in healthy adult volunteers. Antimicrob Agents Chemother (2008) 0.84
In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus. Antimicrob Agents Chemother (2010) 0.83
Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure. Clin Pharmacokinet (2016) 0.82
Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization. Antimicrob Agents Chemother (2013) 0.81
Hsp70 and the Cochaperone StiA (Hop) Orchestrate Hsp90-Mediated Caspofungin Tolerance in Aspergillus fumigatus. Antimicrob Agents Chemother (2015) 0.81
Effect of fluid loading during hypovolaemic shock on caspofungin pharmacokinetic parameters in pig. Crit Care (2011) 0.81
Trailing or paradoxical growth of Candida albicans when exposed to caspofungin is not associated with microsatellite genotypes. Antimicrob Agents Chemother (2010) 0.80
Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans. Antimicrob Agents Chemother (2008) 0.79
In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin. Antimicrob Agents Chemother (2007) 0.79
Effect of caspofungin on metabolite profiles of Aspergillus species determined by nuclear magnetic resonance spectroscopy. Antimicrob Agents Chemother (2007) 0.78
The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus. Antimicrob Agents Chemother (2015) 0.77
Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections. Antimicrob Agents Chemother (2011) 0.77
Anidulafungin in the treatment of invasive fungal infections. Ther Clin Risk Manag (2008) 0.75
Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2015) 0.75
Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections. Clin Med Insights Pediatr (2012) 0.75
Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice. Antimicrob Agents Chemother (2015) 0.75
Anidulafungin and its role in candida infections. Infect Drug Resist (2009) 0.75
The antifungal caspofungin increases fluoroquinolone activity against Staphylococcus aureus biofilms by inhibiting N-acetylglucosamine transferase. Nat Commun (2016) 0.75
Anidulafungin: an evidence-based review of its use in invasive fungal infections. Core Evid (2008) 0.75
Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats. PLoS One (2017) 0.75
Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization. Front Microbiol (2017) 0.75
Caspofungin Increases Fungal Chitin and Eosinophil and γδ T Cell-Dependent Pathology in Invasive Aspergillosis. J Immunol (2017) 0.75
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis (2005) 13.97
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis (2010) 4.98
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis (2005) 4.31
Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother (2010) 4.31
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis (2006) 3.57
Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest (2003) 3.31
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother (2011) 3.04
Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis (2008) 2.65
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis (2006) 2.45
Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica (2006) 2.41
Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am (2006) 2.26
Antifungal drug resistance of pathogenic fungi. Lancet (2002) 2.20
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis (2011) 2.17
Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol (2004) 2.15
Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis (2010) 2.15
Pathogenesis of mucormycosis. Clin Infect Dis (2012) 2.14
Polymyxins: wisdom does not always come with age. Clin Infect Dis (2013) 2.13
Glucocorticoids and invasive fungal infections. Lancet (2003) 2.11
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother (2008) 2.06
Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis (2005) 2.06
Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol (2005) 1.98
Agreement among measurements and estimations of glomerular filtration in children with cancer. Pediatr Blood Cancer (2014) 1.98
Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis (2012) 1.96
Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol (2003) 1.96
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation (2006) 1.94
Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol (2012) 1.93
Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect (2011) 1.90
Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis (2008) 1.88
The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs (2003) 1.86
Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev (2011) 1.82
Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. Antimicrob Agents Chemother (2007) 1.76
Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother (2005) 1.75
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis (2004) 1.74
Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis (2002) 1.74
Diagnosis of invasive mold infection by real-time quantitative PCR. Am J Clin Pathol (2003) 1.73
Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer (2009) 1.69
Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 1.69
Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.68
Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Infect (2010) 1.67
Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.67
Breast implant infections: is cefazolin enough? Plast Reconstr Surg (2010) 1.67
Gliotoxin production in Aspergillus fumigatus contributes to host-specific differences in virulence. J Infect Dis (2008) 1.64
Tuberculosis: a benign impostor. AJR Am J Roentgenol (2010) 1.62
Escherichia coli Pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin Infect Dis (2010) 1.60
The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med (2002) 1.60
Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis (2010) 1.58
Pulmonary mucormycosis. Semin Respir Crit Care Med (2011) 1.58
Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol (2008) 1.58
Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis (2008) 1.57
Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis (2013) 1.56
Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc (2008) 1.56
Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis (2010) 1.55
Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis (2007) 1.54
Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A (2008) 1.54
Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res (2010) 1.52
Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother (2012) 1.52
Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) (2003) 1.51
Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. Blood (2004) 1.51
How I treat mucormycosis. Blood (2011) 1.51
The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis (2011) 1.49
Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. J Infect Dis (2013) 1.49
Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2002) 1.47
Aminopeptidase N inhibitors and SARS. Lancet (2003) 1.47
Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis (2005) 1.47
Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis (2006) 1.46
Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother (2010) 1.46
Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis (2006) 1.46
Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clin Infect Dis (2012) 1.45
Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis (2012) 1.45
Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol (2012) 1.44